DEF 14A: Monopar Therapeutics Seeks Stockholder Approval for Reverse Stock Split and Incentive Plan Amendment

Monopar Therapeutics is asking stockholders to approve a reverse stock split and an amendment to their stock incentive plan at the upcoming annual meeting on August 5, 2024.

Summary

• Monopar Therapeutics is holding its Annual Meeting of Stockholders on August 5, 2024, at its headquarters in Wilmette, IL.
• Stockholders of record as of July 12, 2024, are eligible to vote on several proposals.
• The proposals include the election of six directors, ratification of BPM LLP as the independent accounting firm, approval of a reverse stock split (between 1-for-2 and 1-for-20), and an amendment to the 2016 Stock Incentive Plan to increase the number of shares available for grant.
• The Board of Directors unanimously recommends voting FOR all proposals.
• The company is seeking approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The closing price of Monopar's common stock on July 17, 2024, was $0.71.
• The proposed reverse stock split ratio will be between 1-for-2 and 1-for-20, to be determined by the Board.
• The company is also seeking to amend the 2016 Stock Incentive Plan to increase the aggregate number of shares authorized for issuance by 2,000,000, from 5,100,000 to 7,100,000 shares.
• As of June 14, 2024, there were 1,847,473 shares available for future stock award grants under the 2016 Plan.
• The company believes the additional shares are needed to attract and retain talent.
• If the reverse stock split is implemented, the number of outstanding shares of voting common stock would be reduced to approximately 8,784,088 at a ratio of 1-for-2, or 878,409 at a ratio of 1-for-20, based on 17,568,175 shares outstanding on June 14, 2024.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting necessary information for stockholders to make informed decisions. The need for a reverse stock split suggests underlying financial challenges, but the proposed solutions are presented as positive steps forward.

Positives

• The proposed reverse stock split aims to increase the stock price to meet Nasdaq's minimum bid requirement, potentially improving investor confidence and access to capital.
• Increasing the number of shares available under the 2016 Stock Incentive Plan could help attract and retain key employees and consultants, aligning their interests with those of the stockholders.
• The Board is actively addressing the Nasdaq compliance issue and seeking stockholder input on important corporate governance matters.

Negatives

• The company's stock price is currently below the Nasdaq minimum bid price, indicating potential financial challenges.
• A reverse stock split could be viewed negatively by some investors and may not guarantee a sustained increase in the stock price.
• The company has withheld annual stock grants to the Board and certain officers in order to preserve shares under the plan due to the depressed stock valuation.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting, negatively impacting the stock's liquidity and the company's ability to raise capital.
• The reverse stock split may not result in a sustained increase in the stock price, and the market capitalization could decrease.
• The increased proportion of unissued authorized shares could have potential anti-takeover and dilutive effects.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements through the proposed reverse stock split and continue to attract and retain talent with the amended stock incentive plan.

Management Comments

• The Board of Directors has unanimously approved the proposals and recommends that you vote FOR each of the six director nominees; FOR the ratification of the selection of BPM LLP; FOR the approval to amend the Companys Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares; and FOR the amendment of the 2016 Stock Incentive Plan.

Industry Context

Many small-cap biotech companies face challenges in maintaining stock prices above the Nasdaq minimum bid requirement, often resorting to reverse stock splits to regain compliance. Stock incentive plans are a common tool in the biotech industry to attract and retain talent in a competitive market.

Comparison to Industry Standards

• Reverse stock splits are a relatively common strategy for companies facing delisting from exchanges like Nasdaq, with companies such as Agenus Inc. and Ocugen Inc. having recently undertaken similar actions.
• Stock incentive plans are a standard component of compensation packages in the biotechnology industry, with companies like BioMarin Pharmaceutical and Raptor Pharmaceuticals (where Monopar's executives previously worked) utilizing equity-based compensation to align employee interests with shareholder value.
• The size of the proposed increase in shares available under the stock incentive plan (2,000,000 shares) should be compared to the company's current market capitalization and burn rate to assess its potential dilutive impact, similar to how analysts evaluate such proposals for companies like Glycomine Inc. and Thiogenesis Therapeutics Corp.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the potential reverse stock split and the dilution from the increased shares available under the stock incentive plan.
• Employees and consultants may benefit from the increased availability of equity-based compensation.
• The company's ability to attract and retain talent and maintain its Nasdaq listing could impact its long-term viability and success.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on August 5, 2024.
• The Board will determine the specific ratio for the reverse stock split if approved.
• The company will file the amendment to the Certificate of Incorporation with the Secretary of State of Delaware if the reverse stock split is approved and implemented.
• The company plans to issue annual stock grants for 2024 once the amendment to the 2016 Stock Incentive Plan is approved.

Key Dates

Keywords

reverse stock split, stock incentive plan, annual meeting, Nasdaq compliance, director election, BPM LLP, Monopar Therapeutics, stockholders